Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tandem Diabetes Care (TNDM) Stock Price & Analysis

1,478 Followers

TNDM Stock Chart & Stats

$18.77$0.06(0.32%)
At close: 4:00 PM EST
$15$17.5$20$22.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$18.46 - $19.76
52-Week Range
$12.26 - $29.65
Previous Close
$18.71
Volume
N/A
Average Volume (3M)
2.47M
Market Cap
$1.31B
Enterprise Value
$1.43B
Total Cash (Recent Filing)
$443.08M
Total Debt (Recent Filing)
$736.54M
Price to Earnings (P/E)
―
Beta
0.69
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Supply Economics

Consumable supplies create recurring revenue after each pump placement, supporting customer lifetime value beyond the initial hardware sale. Higher-than-expected monthly supply ASPs and expanding pharmacy access can strengthen monetization as the installed base grows and renews.

Improving Growth And Margins

Revenue growth combined with expanding gross and adjusted EBITDA margins indicates improving operating leverage rather than growth purchased solely through higher costs. Sustained margin progression would increase internal funding capacity and support more durable earnings improvement.

Product Pipeline And Innovation

A potential tubeless automated insulin delivery product broadens Tandem’s product architecture and may address users seeking greater convenience. Additional wear locations, infusion-set advances, and future closed-loop development provide multiple avenues for product-led adoption over the next several years.

Bears Say

High Leverage

The sharply more leveraged capital structure reduces financial flexibility and makes results more sensitive to operating volatility. With a thinner equity base and materially higher debt relative to equity, Tandem has less capacity to absorb setbacks or fund expansion without added financing pressure.

Unprofitable And Cash-consuming

Although losses have narrowed, Tandem has not yet established consistent profitability or positive cash generation. Continued operating and free-cash-flow deficits can constrain investment flexibility, increase reliance on its balance sheet, and delay the conversion of revenue growth into durable shareholder returns.

Pharmacy Transition Headwinds

The slower pharmacy transition is a structural channel change that is already creating revenue headwinds because pump adoption is outpacing supply conversions. This can disrupt near-term revenue mix and delay recurring supply economics while prescription workflows and customer behavior continue to adjust.

Tandem Diabetes Care News

TNDM FAQ

What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $12.26 and its highest was $29.65 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.31B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 104 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Nov 05, 2026. The company reported -$0.102 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.143.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is 0.10.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 69,793,846 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.102 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went down -6.003%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Hedge funds hold Tandem Diabetes Care shares: the largest hedge-fund position in Tandem Diabetes Care is 71,886,722 shares, and hedge funds increased their holdings by 1.9M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology